Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Communiqué de presse: Dupixent® (dupilumab) : publication de résultats positifs de phase III chez l’adulte et l’adolescent atteints d’œsophagite à éosinophiles dans le New England Journal of Medicine
10:30pm, Wednesday, 21'st Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) : publication de résultats positifs de phase III chez l’adulte et l’adolescent atteints d’œsophagite à éosinophiles dans le New England Journal of Medicine
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
Sanofi: Informations relatives au nombre de droits de vote et d'actions Novembre 2022
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Communiqué de presse: Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologie
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologie
Sanofi: Information concerning the total number of voting rights and shares November 2022
06:00am, Monday, 19'th Dec 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
12:30pm, Friday, 16'th Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
Communiqué de presse: Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’UE pour le traitement de l’œsophagite à éosinophiles
12:30pm, Friday, 16'th Dec 2022 GlobeNewswire Inc.
Le CHMP recommande l’approbation de Dupixent® (dupilumab) dans l’UE pour le traitement de l’œsophagite à éosinophiles
Communiqué de presse: Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement du prurigo nodulaire
06:00am, Thursday, 15'th Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) : premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement du prurigo nodulaire
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
06:00am, Thursday, 15'th Dec 2022 GlobeNewswire Inc.
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
Amgen wins battle for Horizon Therapeutics, bolstering its rare-disease portfolio
12:47pm, Tuesday, 13'th Dec 2022 MarketWatch
Amgen Inc. is acquiring Dublin-based Horizon Therapeutics in a roughly $28 billion deal that is the biggest in the healthcare sector in 2022.
Amgen reportedly in talks to buy Horizon Therapeutics
06:36am, Monday, 12'th Dec 2022 MarketWatch
The U.S. biotechnology company AMGN was the last of three suitors standing in an auction for Horizon, according to sources cited by The Wall Street Journal.
Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)
06:21pm, Sunday, 11'th Dec 2022 GlobeNewswire Inc.
Communiqué de presse : Annonce de Sanofi au sujet de Horizon Therapeutics plc (“Horizon”)
06:21pm, Sunday, 11'th Dec 2022 GlobeNewswire Inc.Santander UK fined £107mln by financial regulator FCA for anti-money laundering failures
03:47am, Friday, 09'th Dec 2022
The UK arm of Spanish banking group Banco Santander has been fined £107.79mln by the Financial Conduct Authority (FCA) after the regulator found “serious and persistent gaps” in the bank's anti-
Santander U.K. fined $131.4 million for anti-money-laundering failures
02:56am, Friday, 09'th Dec 2022
According to the FCA, Santander UK PLC has failed to properly oversee and manage its AML systems between December 2012 and October 2017, which affected the account oversight of more than 560,000 busin
